Solvet, a Calgary-based company, has received approval from the U.S. Food and Drug Administration (FDA) to distribute its equine ivermectin product in the United States as a measure to combat screwworm infestations. The liquid form of ivermectin, developed by Solvet, stands out as it is aqueous-based and more concentrated than traditional paste formulations, making it easier to administer to horses.
Founded in 2009 by two former University of Calgary professors, Solvet has evolved into one of Canada’s leading veterinary pharmaceutical enterprises. Ivermectin, a well-known anti-parasitic drug, is effective against various parasites, including screwworm, a fly species native to parts of North America. Female screwworm flies lay eggs on open wounds of animals like horses, cattle, and occasional humans, leading to severe tissue damage, infections, and potential fatalities.
In the past, screwworm infestations caused significant economic losses for ranchers in the U.S. and Mexico until the successful eradication of the pest using the sterile insect technique. This method involves releasing sterilized male flies into the environment to prevent the reproduction of screwworm populations. However, recent reports indicate the reemergence of screwworm infestations in North America, raising concerns among agricultural authorities.
To address the screwworm resurgence, Solvet’s ivermectin liquid has been authorized by the FDA for short-term prevention in horses with screwworm exposure. This emergency approval aims to safeguard animal welfare by targeting early larval stages of the parasite. While the product is labeled for broader use against multiple parasites in Canada, its U.S. distribution is limited to combating screwworm specifically.
Experts like John Gilleard from the University of Calgary emphasize the importance of judicious use of ivermectin to prevent resistance in parasites and minimize environmental impacts. Despite the current low risk of screwworm in Canada, authorities remain vigilant and cooperate with U.S. counterparts to monitor developments and adjust preventive measures accordingly.
Solvet views this situation as an opportunity to expand its presence internationally, particularly in the U.S., by offering solutions in critical times of need. This strategic move not only benefits animal health but also opens doors for economic growth and research funding in Alberta.
In conclusion, Solvet’s FDA-approved ivermectin liquid presents a proactive approach to combat screwworm infestations and underscores the importance of responsible usage to mitigate risks associated with parasite resistance and environmental implications.